Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

October 2022 | 64 pages | ID: D4E107CB3998EN
Global Markets Direct

Abstracts

Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Drugs In Development, 2022, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 4, 4, 4, 1, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Phase 0 stages comprises 1 molecules, respectively.

Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Dermatomyositis - Overview
Dermatomyositis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Dermatomyositis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dermatomyositis - Companies Involved in Therapeutics Development
Adienne Pharma & Biotech SA
Alexion Pharmaceuticals Inc
Argenx SE
Avotres Inc
Cellular Biomedicine Group Ltd
CSL Ltd
Ermium Therapeutics SAS
Fresh Tracks Therapeutics Inc
Galapagos NV
GNI Group Ltd
Horizon Therapeutics Plc
Juventas Cell Therapy Ltd
Kezar Life Sciences Inc
NovelMed Therapeutics Inc
Paean Biotechnology Inc
Pfizer Inc
Priovant Therapeutics Inc
Santhera Pharmaceuticals Holding AG
Dermatomyositis - Drug Profiles
AVT-001 - Drug Profile
Product Description
Mechanism Of Action
begelomab - Drug Profile
Product Description
Mechanism Of Action
Biologic for Central Nervous System, Infectious Disease, Musculoskeletal Disorders and Respiratory - Drug Profile
Product Description
Mechanism Of Action
brepocitinib tosylate - Drug Profile
Product Description
Mechanism Of Action
CNCT-19 - Drug Profile
Product Description
Mechanism Of Action
CXCR4 biased agonist - Drug Profile
Product Description
Mechanism Of Action
daxdilimab - Drug Profile
Product Description
Mechanism Of Action
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
FRTX-10 - Drug Profile
Product Description
Mechanism Of Action
gefurulimab - Drug Profile
Product Description
Mechanism Of Action
GLPG-3667 - Drug Profile
Product Description
Mechanism Of Action
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibodies for Dermatomyositis - Drug Profile
Product Description
Mechanism Of Action
ONX-0914 - Drug Profile
Product Description
Mechanism Of Action
PF-06823859 - Drug Profile
Product Description
Mechanism Of Action
pirfenidone - Drug Profile
Product Description
Mechanism Of Action
PN-101 - Drug Profile
Product Description
Mechanism Of Action
ravulizumab LA - Drug Profile
Product Description
Mechanism Of Action
RD-1301 - Drug Profile
Product Description
Mechanism Of Action
tofacitinib citrate ER - Drug Profile
Product Description
Mechanism Of Action
vamorolone - Drug Profile
Product Description
Mechanism Of Action
zetomipzomib - Drug Profile
Product Description
Mechanism Of Action
Dermatomyositis - Dormant Projects
Dermatomyositis - Discontinued Products
Dermatomyositis - Product Development Milestones
Featured News & Press Releases
May 03, 2022: Kezar announces topline results from PRESIDIO trial of zetomipzomib for the treatment of dermatomyositis and polymyositis
Aug 23, 2021: Kezar Life Sciences announces completion of enrollment of its Phase 2 PRESIDIO clinical trial of KZR-616 in polymyositis and dermatomyositis
May 26, 2021: Kezar Life Sciences to host virtual MISSION phase 1b data update call at EULAR 2021
Nov 05, 2020: Kezar highlights broad therapeutic potential of KZR-616 during ACR Convergence 2020
Oct 23, 2020: Kezar Life Sciences announces Orphan Drug Designations for KZR-616 for the treatment of polymyositis and dermatomyositis
Sep 10, 2020: Kezar Life Sciences to present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology
Sep 09, 2020: Avotres received the approval letter from the IRB to initiate human ex vivo studies of AVT001
Jun 06, 2018: GNI Group Initiates Etuary Phase III Trial in China for CTD-ILD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Dermatomyositis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dermatomyositis - Pipeline by Adienne Pharma & Biotech SA, 2022
Dermatomyositis - Pipeline by Alexion Pharmaceuticals Inc, 2022
Dermatomyositis - Pipeline by Argenx SE, 2022
Dermatomyositis - Pipeline by Avotres Inc, 2022
Dermatomyositis - Pipeline by Cellular Biomedicine Group Ltd, 2022
Dermatomyositis - Pipeline by CSL Ltd, 2022
Dermatomyositis - Pipeline by Ermium Therapeutics SAS, 2022
Dermatomyositis - Pipeline by Fresh Tracks Therapeutics Inc, 2022
Dermatomyositis - Pipeline by Galapagos NV, 2022
Dermatomyositis - Pipeline by GNI Group Ltd, 2022
Dermatomyositis - Pipeline by Horizon Therapeutics Plc, 2022
Dermatomyositis - Pipeline by Juventas Cell Therapy Ltd, 2022
Dermatomyositis - Pipeline by Kezar Life Sciences Inc, 2022
Dermatomyositis - Pipeline by NovelMed Therapeutics Inc, 2022
Dermatomyositis - Pipeline by Paean Biotechnology Inc, 2022
Dermatomyositis - Pipeline by Pfizer Inc, 2022
Dermatomyositis - Pipeline by Priovant Therapeutics Inc, 2022
Dermatomyositis - Pipeline by Santhera Pharmaceuticals Holding AG, 2022
Dermatomyositis - Dormant Projects, 2022
Dermatomyositis - Dormant Projects, 2022 (Contd..1)
Dermatomyositis - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Dermatomyositis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022